Table 1.
Baseline patient characteristics and disease phenotype according to the Montreal classification (baseline cohort)
| CD | UC | |
|---|---|---|
| N = 148 | N = 80 | |
| Female | 95 (64%) | 34 (43%) |
| Age (years: median + IQR) | 44 (32–55) | 50 (40–63) |
| Smoking | 42 (28%) | 3 (4%) |
| (IBD-related) surgery | 62 (42%) | 2 (3%) |
| Age at diagnosis | ||
| A1 <16 years | 7 (5%) | |
| A2 17–40 years | 101 (68%) | |
| A3 ≥41 years | 40 (27%) | |
| Disease phenotype | ||
| B1 Non-stricturing/non-penetrating | 101 (68%) | |
| B2 Stricturing | 29 (20%) | |
| B3 Penetrating | 21 (14%) | |
| Disease location | ||
| L1 Ileal | 41 (28%) | |
| L2 Colonic | 37 (25%) | |
| L3 Ileocolonic | 70 (47%) | |
| L4 Proximal | 8 (5%) | |
| Extent of disease | ||
| E1 Proctitis | 6 (8%) | |
| E2 Left-sided | 50 (62%) | |
| E3 Pancolitis | 24 (30%) | |
| Medication | ||
| Mesalazines | 21 (14%) | 33 (41%) |
| Corticosteroids | 17 (12%) | 3 (4%) |
| Thiopurines | 38 (26%) | 17 (21%) |
| Methotrexate | 6 (4%) | 3 (4%) |
| Biologicals | 65 (44%) | 20 (25%) |
| No medication | – | 4 (5%) |